CERE PR Newswire
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
PR Newswire
Wed, Dec 6, 2023 at 1:30 PM PST10 min read
In This Article:
ABBV
+1.25%
CERE
+3.77%
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain
Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline
Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions
Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion
AbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CT
--------------------
I love biotech investing :--)
Kiwi
